Journal of Cancer Research and Therapeutics Close
 

Figure 3: Comparison of the percentage of viable B cell derived from chronic lymphocytic leukemia patients at the expose of all-tans retinoic acid, interleukin21, and rituximab alone and combinations of binary and ternary relative to each other after 20 h culture. The columns indicate the mean ± standard error

Figure 3: Comparison of the percentage of viable B cell derived from chronic lymphocytic leukemia patients at the expose of all-tans retinoic acid, interleukin21, and rituximab alone and combinations of binary and ternary relative to each other after 20 h culture. The columns indicate the mean ± standard error